Content about Intensive care medicine

February 11, 2013

Home nutrition support team interventions improved patient care and potentially prevented an estimated 429 hospital days over a three-month period, at a cost savings of more than $850,000, according to new data presented by Walgreens Infusion Services at the American Society for Parenteral and Enteral Nutrition Clinical Nutrition Week meeting Monday in Phoenix.

DEERFIELD, Ill. — Home nutrition support team interventions improved patient care and potentially prevented an estimated 429 hospital days over a three-month period, at a cost savings of more than $850,000, according to new data presented by Walgreens Infusion Services at the American Society for Parenteral and Enteral Nutrition Clinical Nutrition Week meeting Monday in Phoenix. 

December 27, 2012

Walgreens Infusion Services has been selected as a contracted provider of a new injectable medication that helps patients with short bowel syndrome.

DEERFIELD, Ill. — Walgreens Infusion Services has been selected as a contracted provider of a new injectable medication that helps patients with short bowel syndrome get more — or all — of their nutrients orally, reducing their dependence on intravenous parenteral nutrition, the division announced Wednesday.

October 25, 2011

Eli Lilly is withdrawing one of its drugs from the market after clinical trials showed it to be ineffective.

INDIANAPOLIS — Eli Lilly is withdrawing one of its drugs from the market after clinical trials showed it to be ineffective.

The drug maker announced Tuesday the withdrawal of Xigris (drotrecogin alfa [activated]) from all markets following results of the "PROWESS-SHOCK" study, which found that it did not produce a statistically significant reduction in 28-day, all-cause death in patients with septic shock. The company said there were no new findings regarding the drug's safety profile.

May 24, 2011

Drug maker Eli Lilly is partnering with two private investor groups to form a new biotech company based in central Indiana, the company said Monday.

INDIANAPOLIS — Drug maker Eli Lilly is partnering with two private investor groups to form a new biotech company based in central Indiana, the company said Monday.

Lilly signed a deal with Care Capital and NovaQuest Capital to establish BioCritica, a privately held biotechnology company that will focus on continued U.S. development and commercialization of the severe sepsis treatment Xigris (drotrecogin alfa [activated]). The new company also will expand its portfolio of critical care medicines for hospitals.

January 25, 2011

Eisai will not seek regulatory approval for a drug to treat severe sepsis after getting lackluster results from a late-stage clinical trial, the drug maker said Tuesday.

WOODCLIFF LAKE, N.J. — Eisai will not seek regulatory approval for a drug to treat severe sepsis after getting lackluster results from a late-stage clinical trial, the drug maker said Tuesday.

Eisai said a phase-3 trial of the drug eritoran found the drug did not significantly reduce mortality in patients with the condition compared with placebo.

Severe sepsis causes about 215,000 deaths in the United States every year, with a mortality rate of about 30%.